The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
The Medicines Patent Pool (MPP) welcomes the opportunity to provide inputs to the Draft Roadmap on access to medicines and vaccines.
We note that one of the deliverables considered as potentially having significant impact on access to safe, effective and affordable medicines is supporting the expansion of the MPP to essential medicines under patent. This expansion is in fact already in process.
The MPP was established by Unitaid as a mechanism to promote innovation and access to medicines through public health-oriented licensing. It is a concrete example in moving towards Universal Health Coverage by enabling over 100 countries to get faster access to new HIV, hepatitis C and TB treatments at affordable prices and in suitable formulations.
With the support of the Swiss Development and Cooperation Agency, the MPP recently undertook a feasibility study to assess the potential for the MPP’s patent pooling model to be applied to patented essential medicines in other therapeutic areas. Following strong s...
Geneva, 28 July 2018 - The Medicines Patent Pool (MPP) welcomes the new global guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection published today by the World Health Organization. These guidelines recommend treating all people aged 12 and above living with chronic hepatitis C virus (HCV) infection (with the exception of pregnant women) and recommends the use of pan-genotypic regimens.
The MPP signed a licence agreement for pan-genotypic direct-acting antiviral daclatasvir (DAC) and its combinations with Bristol-Myers Squibb in November 2015. Since then, ten generic manufacturing partners of the MPP signed a licence to produce lower-cost versions of these products for sale in 112 low- and middle-income countries.
Four MPP licensees have already filed daclatasvir (DAC) 30mg and 60mg for regulatory approval through the WHO Prequalification Program and three more plan to do so in 2019. One manufacturer has already received approval from the Expert Review Pan...
Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines
Geneva, 24 May 2018 — The Medicines Patent Pool Foundation (MPP) released its five-year strategic plan during a side event at the 71st World Health Assembly this evening. The strategy calls for renewed efforts to reach people living with HIV, hepatitis C and tuberculosis in low- and middle-income countries (LMICs) with better-adapted, affordable medicines.
Based on a feasibility study also presented at the MPP-partner event, The Path to Universal Health Coverage: Access to Affordable Treatments, the plan supports the expansion of the MPP model to other patented medicines with high medical value, starting with small molecules on the World Health Organization Model List of Essential Medicines (EML).
“Over the past eight years, the MPP has made significant inroads in supporting the scale-up of new antiretrovirals, as well as curative...
“WHO welcomes the announcement that the Medicines Patent Pool is expanding its mandate to include patented medicines on WHO’s Model List of Essential Medicines in its patent pooling and voluntary licensing initiatives. It is a welcome and significant step f...”
Unable to load twitter timeline, please allow cookie